{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:01Z","timestamp":1792813501425,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies with a poor prognosis and limited treatment options. We present a single arm Phase II study of 18 patients with LMD receiving combined ipilimumab and nivolumab until progression or unacceptable toxicity (NCT02939300). The primary end point is overall survival at 3 months (OS3). Secondary end points include toxicity, cumulative time-to-progression at 3 months, and progression-free survival. A Simon two-stage design is used to compare a null hypothesis OS3 of 18% against an alternative of 44%. Median follow up based on patients still alive is 8.0 months (range: 0.5 to 15.9 months). The study has met its primary endpoint as 8 of 18 (OS3 0.44; 90% CI: 0.24 to 0.66) patients are alive at three months. One third of patients have experienced one (or more) grade-3 or higher adverse events. Two patients have discontinued protocol treatment due to unacceptable toxicity (hepatitis and colitis, respectively). The most frequent adverse events include fatigue (N\u2009=\u20097), nausea (N\u2009=\u20096), fever (N\u2009=\u20096), anorexia (N\u2009=\u20096) and rash (N\u2009=\u20096). Combined ipilimumab and nivolumab has an acceptable safety profile and demonstrates promising activity in LMD patients. Larger, multicenter clinical trials are needed to validate these results.<\/jats:p>","DOI":"10.1038\/s41467-021-25859-y","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T13:24:52Z","timestamp":1634045092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":83,"title":["Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis"],"prefix":"10.1038","volume":"12","author":[{"given":"Priscilla K.","family":"Brastianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eudocia Quant","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine V.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugonma","family":"Chukwueke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah Anne","family":"Forst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Eichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Overmoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4885-1157","authenticated-orcid":false,"given":"Aditya","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-7704","authenticated-orcid":false,"given":"Dejan","family":"Juric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibiayi","family":"Dagogo-Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-9243","authenticated-orcid":false,"given":"Michael D.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorg","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3436-8404","authenticated-orcid":false,"given":"Naema","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-6209","authenticated-orcid":false,"given":"Albert E.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Alvarez-Breckenridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Mahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5913-1107","authenticated-orcid":false,"given":"Joana L.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian V.","family":"Nahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela S.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Gerstner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Giobbie-Hurder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-1475","authenticated-orcid":false,"given":"Scott L.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel P.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"25859_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1053\/ctrv.1999.0119","volume":"25","author":"SA Grossman","year":"1999","unstructured":"Grossman, S. A. & Krabak, M. J. Leptomeningeal carcinomatosis. Cancer Treat. Rev. 25, 103\u2013119 (1999).","journal-title":"Cancer Treat. Rev."},{"key":"25859_CR2","doi-asserted-by":"publisher","first-page":"e000507","DOI":"10.1136\/esmoopen-2019-000507","volume":"4","author":"E Le Rhun","year":"2019","unstructured":"Le Rhun, E., Preusser, M., van den Bent, M., Andratschke, N. & Weller, M. How we treat patients with leptomeningeal metastases. ESMO Open 4, e000507 (2019).","journal-title":"ESMO Open"},{"key":"25859_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(10)70034-6","volume":"11","author":"P Beauchesne","year":"2010","unstructured":"Beauchesne, P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol. 11, 871\u2013879 (2010).","journal-title":"Lancet Oncol."},{"key":"25859_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1136\/pgmj.56.653.149","volume":"56","author":"R Boyle","year":"1980","unstructured":"Boyle, R., Thomas, M. & Adams, J. H. Diffuse involvement of the leptomeninges by tumour\u2014a clinical and pathological study of 63 cases. Postgrad. Med. J. 56, 149\u2013158 (1980).","journal-title":"Postgrad. Med. J."},{"key":"25859_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11060-012-0880-x","volume":"109","author":"MC Chamberlain","year":"2012","unstructured":"Chamberlain, M. C. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J. Neurooncol. 109, 143\u2013148 (2012).","journal-title":"J. Neurooncol."},{"key":"25859_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0929-6646(08)60201-6","volume":"107","author":"TY Chuang","year":"2008","unstructured":"Chuang, T. Y., Yu, C. J., Shih, J. Y., Yang, P. C. & Kuo, S. H. Cytologically proven meningeal carcinomatosis in patients with lung cancer: clinical observation of 34 cases. J. Formos. Med. Assoc. 107, 851\u2013856 (2008).","journal-title":"J. Formos. Med. Assoc."},{"key":"25859_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF01806382","volume":"9","author":"G Clamon","year":"1987","unstructured":"Clamon, G. & Doebbeling, B. Meningeal carcinomatosis from breast cancer: spinal cord vs. brain involvement. Breast Cancer Res. Treat. 9, 213\u2013217 (1987).","journal-title":"Breast Cancer Res. Treat."},{"key":"25859_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JCO.1993.11.3.561","volume":"11","author":"SA Grossman","year":"1993","unstructured":"Grossman, S. A. et al. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J. Clin. Oncol. 11, 561\u2013569 (1993).","journal-title":"J. Clin. Oncol."},{"key":"25859_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1524-4741.2012.01228.x","volume":"18","author":"F Lara-Medina","year":"2012","unstructured":"Lara-Medina, F. et al. Clinical features and prognostic factors in patients with carcinomatous meningitis secondary to breast cancer. Breast J. 18, 233\u2013241 (2012).","journal-title":"Breast J."},{"key":"25859_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/archneur.1974.00490320026003","volume":"30","author":"JR Little","year":"1974","unstructured":"Little, J. R., Dale, A. J. & Okazaki, H. Meningeal carcinomatosis. Clinical manifestations. Arch. Neurol. 30, 138\u2013143 (1974).","journal-title":"Arch. Neurol."},{"key":"25859_CR11","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1212\/WNL.33.12.1565","volume":"33","author":"BW Ongerboer de Visser","year":"1983","unstructured":"Ongerboer de Visser, B. W. et al. Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33, 1565\u20131572 (1983).","journal-title":"Neurology"},{"key":"25859_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1097\/00005792-198201000-00005","volume":"61","author":"ST Rosen","year":"1982","unstructured":"Rosen, S. T. et al. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Medicine 61, 45\u201353 (1982).","journal-title":"Medicine"},{"key":"25859_CR13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cncr.30911","volume":"124","author":"N Wang","year":"2018","unstructured":"Wang, N., Bertalan, M. S. & Brastianos, P. K. Leptomeningeal metastasis from systemic cancer: Review and update on management. Cancer 124, 21\u201335 (2018).","journal-title":"Cancer"},{"key":"25859_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0030-1255220","volume":"30","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain, M. C. Leptomeningeal metastasis. Semin Neurol. 30, 236\u2013244 (2010).","journal-title":"Semin Neurol."},{"key":"25859_CR15","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3171\/jns.1997.87.5.0694","volume":"87","author":"MC Chamberlain","year":"1997","unstructured":"Chamberlain, M. C., Kormanik, P. A. & Barba, D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J. Neurosurg. 87, 694\u2013699 (1997).","journal-title":"J. Neurosurg."},{"key":"25859_CR16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg, S. B. et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 17, 976\u2013983 (2016).","journal-title":"Lancet Oncol."},{"key":"25859_CR17","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long, G. V. et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 19, 672\u2013681 (2018).","journal-title":"Lancet Oncol."},{"key":"25859_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin, K. et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 13, 459\u2013465 (2012).","journal-title":"Lancet Oncol."},{"key":"25859_CR19","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi, H. A. et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N. Engl. J. Med. 379, 722\u2013730 (2018).","journal-title":"N. Engl. J. Med."},{"key":"25859_CR20","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2019.05.019","volume":"116","author":"LEL Hendriks","year":"2019","unstructured":"Hendriks, L. E. L. et al. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. Eur. J. Cancer 116, 182\u2013189 (2019).","journal-title":"Eur. J. Cancer"},{"key":"25859_CR21","doi-asserted-by":"publisher","unstructured":"Prakadan, S. M. et al. Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-021-25860-5 (2021).","DOI":"10.1038\/s41467-021-25860-5"},{"key":"25859_CR22","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S1470-2045(15)00088-1","volume":"16","author":"H Okada","year":"2015","unstructured":"Okada, H. et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 16, e534\u2013e542 (2015).","journal-title":"Lancet Oncol."},{"key":"25859_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-017-4537-5","volume":"167","author":"LY Dirix","year":"2018","unstructured":"Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res. Treat. 167, 671\u2013686 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"25859_CR24","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","volume":"15","author":"M Lim","year":"2018","unstructured":"Lim, M., Xia, Y., Bettegowda, C. & Weller, M. Current state of immunotherapy for glioblastoma. Nat. Rev. Clin. Oncol. 15, 422\u2013442 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"25859_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-016-0702-8","volume":"18","author":"R Duchnowska","year":"2016","unstructured":"Duchnowska, R. et al. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1\/PD-L axis. Breast Cancer Res. 18, 43 (2016).","journal-title":"Breast Cancer Res."},{"key":"25859_CR26","doi-asserted-by":"publisher","first-page":"E1540","DOI":"10.1073\/pnas.1714089115","volume":"115","author":"D Taggart","year":"2018","unstructured":"Taggart, D. et al. Anti-PD-1\/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8(+) T cell trafficking. Proc. Natl Acad. Sci. USA 115, E1540\u2013E1549 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25859-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25859-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T16:03:32Z","timestamp":1669997012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-25859-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["25859"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-25859-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"14 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.K.B. has received compensation for consulting from Lilly, Angiochem, ElevateBio, Voyager Therapeutics,\u00a0Tesaro, Genentech-Roche, SK Life Sciences, Pfizer, Dantari and Speaker\u2019s Honoraria from Genentech-Roche and Merck Sharp & Co. P.K.B. has received research funding (to MGH) from Merck & Co, BMS, Eli Lilly, Mirati\u00a0and Pfizer. J.V.C. has received consulting fees from Sanofi-Genzyme and BMS. D.P.C. has consulted for Lilly and Boston Pharmaceuticals, and has received travel\/speaking fees from Merck. N.U.L. has received institutional research funding from Seattle Genetics, Genentech, Merck, and Pfizer. She has served on an advisory board or consulted for PUMA Biotechnology, Seattle Genetics, and Daichii Sankyo. R.J.S. has received research funding from Amgen and Merck, and served as a paid consultant and\/or on an advisory board for Array BioPharma, Amgen, Asan Biosciences, BMS, Compugen, Genentech, Merck, Novartis, and Replimmune. E.Q.L. has received royalties from Wolters Kluwers (Up to Date, Inc) and has consulted for Lilly. M.D.W. is a consultant at Boston Pharmaceuticals. I.D.J. has received honoraria from Foundation Medicine, consulting fees from Boehringer Ingelheim and AstraZeneca, travel fees from Array and Pfizer, and research support from Array, Genentech, Guardant, and Pfizer. J.D. is a consultant for Unum Therapeutics and Blue Earth Diagnostics and has received royalties from Kluwer Wolters. A.B. reports grants from Genentech, Novartis, Pfizer, Merck, Sanofi, Radius Health, Immunomedics, Biothernostics Inc. and personal fees from Biothernostics Inc., Pfizer, Novartis, Genentech, Merck, Radius Health, Immunomedics, Taiho, Sanofi, Diiachi Pharma\/Astra Zeneca, Puma, Phillips, Eli Lilly and Foundation Medicine, outside the submitted work. B.O. has received clinical trial support from Eisai and Incyte. D.F. holds shares in Eli Lilly. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5954"}}